Onco Actu du 11 mars 2020

	2. ETIOLOGIE
Higher Concentrations Of IGF-1 Are A Probable Cause of Breast Cancer [Annals of Oncology Press Release] “Although levels of IGF-1 in the blood are potentially modifiable it is currently unknown how long an intervention aimed at altering IGF-1 concentrations would have to be applied in order to have a measurable effect or whether there could be other adverse impacts of such an intervention.”
	3.1.1 PRÉVENTION - TABAC - E-CIGS
FDA Warns Retailers, Manufacturers to Remove Unauthorized E-Cigarette Products from Market [FDA] Agency Continues to Conduct Inspections to Ensure Compliance with Focus on Targeted Unauthorized Flavored E-Cigarette Products Appealing to Youth.
	4.1 DÉP., DIAG. & PRONO. - PROSTATE
Prostate Cancer: Combined Biopsy Strategy Makes for More Accurate Diagnosis [NIH Director's Blog] NIH researchers and their colleagues recently found that combining the 12-point biopsy with magnetic resonance imaging (MRI)-targeted biopsy during the same session more accurately diagnoses prostate cancer than either technique alone.
	4.16 DÉP., DIAG. & PRONO. - PANCRÉAS
New Study Identifies Valuable Tool for Treating Pancreatic Cancer Patients [University of Colorado] The study offers the advantage of estimating the outcome of each patient before an operation, and regardless of local anatomic features of the tumor, to understand if a patient qualifies or not for an operation based on his or her long-term predicted survival. The use of the nomogram in clinical practice should be proposed after a prospective validation.
	4.2 DÉP., DIAG. & PRONO. - GÉNOME
Older women with breast cancer may benefit from genetic testing [Stanford Medicine] Postmenopausal women with breast cancer are as likely as Ashkenazi Jewish women to carry inherited breast-cancer mutations that can inform treatment, a Stanford study found.
Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted [Genome Web] Using data from the Women's Health Initiative, they found that more than 3 percent of postmenopausal women with breast cancer but no other disease risk factors carried pathogenic variants in breast-cancer linked genes.
Genetic test could pick out 'ultra high risk' bone marrow cancer patients [Institute of Cancer Research] One quarter of the patients, 81 in total, had cancers with the so-called SKY92 signature – a pattern of gene activity involving 92 genes linked to high risk status.
	4.7 DÉP., DIAG. & PRONO. - COL DE L'UTÉRUS
Roche receives FDA approval for CINtec PLUS Cytology test to aid clinicians in improving cervical cancer prevention [Roche] The CINtec PLUS Cytology test identifies those women whose HPV infections are most likely to be associated with cervical pre-cancers. It enables clinicians to more confidently determine which women should be referred to immediate further diagnostic procedures, helping to prevent women from developing more advanced cervical disease.
	4.9 DÉP., DIAG. & PRONO. - SEIN
Tomosynthesis Outperforms Digital Mammography in Five-Year Study [RSNA] A new study published in the journal Radiology has found that the advantages of digital breast tomosynthesis (DBT) over digital mammography (DM), including increased cancer detection and fewer false positive findings, are maintained over multiple years and rounds of screening.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Possible breast cancer treatment could go to clinical trial immediately as scientists spot target in 'normal' cells [University of Sussex] Using samples from triple negative breast cancer patients, researchers found that overall survival was markedly worse when levels of the protein PIK3Cδ were high in surrounding healthy tissue. Interestingly, this was not the case for the other two subtypes of breast cancer(ΕRα+ and HER2+).
	5.10 TRAITEMENTS - ESSAIS
FDA’s Draft Guidance Will Improve Evidence Base for Older Adults with Cancer [ASCO] This draft guidance signals to researchers and sponsors that clinical trials should include older adults with cancer when they can be safely and ethically enrolled.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis [Cellectis] Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies.
J&J's favorite CAR-T developer, currently owned by a Chinese CRO, is laying the groundwork for US IPO [EndPoints] Legend was a virtual unknown until it turned up at ASCO in 2017 with early data on its BCMA CAR-T contender showing a 100% objective response rate and a 94% clinical remission rate among a small group of multiple myeloma patients.
	5.2 PHARMA
Takeda's Ninlaro swings and misses in newly diagnosed myeloma [Fierce Pharma] It’s a blow for Takeda, which was looking to follow Johnson & Johnson’s Darzalex into the more lucrative first-line setting, where there are more patients who tend to stay on therapy for longer.
2 newer multiple myeloma drugs fall short in bid for wider market [Biopharma Dive] Buying Celgene and its multiple myeloma drug business means Empliciti is less critical to Bristol Myers' future growth. Ninlaro's failure in Takeda's Phase 3 study, by contrast, is a bit more of a blow for the Japanese drugmaker, which has a less extensive cancer drug portfolio.
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial [Takeda] The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance.
	5.2.6 PHARMA - BIOTECH
Karyopharm's controversial Xpovio could see wider myeloma market after latest trial win [Fierce Pharma] In the phase 3 Boston study, subjects on SVd lived a median of 13.93 months without their cancer progressing, versus 9.46 months in the Vd group, meaning patients lived 47% longer without disease worsening.
	6. LUTTE CONTRE LES CANCERS
National Comprehensive Cancer Network Releases Recommendations for Standardizing Quality Measurements in Oncology [NCCN] The committee reviewed 528 existing oncology quality measures and new measure concepts that could be appropriate for development. This list was narrowed down into 22 recommendations.
	6.1 OBSERVATION
Dramatic increase in bowel cancer in young adults in England [University of Bristol] The study highlights that the increase in bowel cancer incidence in young people is predominantly driven by an increase in tumours of the lowermost portion of the bowel, specifically the sigmoid colon and rectum.
Disparities in childhood cancer survival biggest for most-treatable tumors [Reuters] For the study, researchers examined data on 67,061 kids diagnosed with cancer at age 10, on average. Most often, these children had leukemia, brain tumors or an immune system cancer known as non-Hodgkin lymphoma.
	6.9 CONTROVERSES
Want to do better science? Admit you’re not objective [Nature] Scientists need both history and the social sciences to develop the intellectual tools to think critically about their research and how it affects society. This isn’t just helpful — it’s vital.